all report title image
  • Published On : Aug 2022
  • Code : CMI5153
  • Industry : Pharmaceutical
  • Pages : 185
  • Formats :

Calcium channel blocker are available in short acting and long acting form. The response of short acting medication is quick as compare to long acting calcium channel blocker drugs. Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac, others), Felodipine, Isradipine, Nicardipine are the type of calcium channel blocker drug used for the treatment of coronary artery disease, chest pain (angina), irregular heartbeats (arrhythmia) and blood vessel conditions, such as Raynaud's disease.

The global calcium channel blocker drugs market is estimated to be valued at US$ 14,285.3 million in 2022 and expected to exhibit a CAGR of 5.2% over the forecast period (2022-2030).

Figure 1. Global Calcium Channel Blocker Drugs Market Share (%) in Terms of Value, by Region, 2022

Calcium Channel Blocker Drugs  | Coherent Market Insights

Increasing prevalence of hypertension is expected to aid in the growth of the global calcium channel blocker drugs market

According to the World Health Organization 2021, hypertension is a major cause of premature death worldwide.

Moreover, according to the Million Hearts managed by the Centers for Disease Control and Prevention, around 1 out of 2 adults in the U.S. suffer from hypertension. In addition, around 91.7 million adult in the U.S. are recommended prescription medication with lifestyle modifications.

CMI table icon

Calcium Channel Blocker Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 14,285.3 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 5.2% 2030 Value Projection: US$ 21,489.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Benzothizepine, Dihydropyridine, Phenylalkylamine
  • By Disease Indications: Hypertension, Chest Pain, Arrhythmias
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:

Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc

Growth Drivers:
  • Rising incidence of hypertension
  • Launches and approval of calcium channel blocker drug 
Restraints & Challenges:
  • Side effect associated with calcium channel blocker drug 

Figure 2. Global Calcium Channel Blocker Drugs Market Share (%), by Drug Class, 2022

Calcium Channel Blocker Drugs  | Coherent Market Insights

Global Calcium Channel Blocker Drugs Market: Restraint

Side effects associated with to calcium channel blockers drug such as, headache, rapid heart rate, edema and constipation are expected to inhibit the market growth during the forecast period for the companies and products.

Key Players

Major players operating in the global calcium channel blocker drugs market include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,

Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.

Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ’s function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease – this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.

Market Dynamics

Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.

Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period

For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.

Key features of the study:

  • This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global calcium channel blocker drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market

Detailed Segmentation:

  • Global Calcium Channel Blocker Drugs Market, By Drug Class:
    • Benzothizepine
    • Dihydropyridine
    • Phenylalkylamine
  • Global Calcium channel blocker drugs market, By Disease Indication:
    • Hypertension
    • Chest Pain
    • Arrhythmias
    • Others (Blood vessel conditions, Coronary Artery Disease etc.)
  • Global Calcium Channel Blocker Drugs Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Calcium Channel Blocker Drugs Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest Of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Bausch Health*
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd
    • Lupin
    • Arbor Pharmaceuticals
    • GlaxoSmithKline Plc
    • Biopharma
    • Sofgen Pharmaceuticals
    • Glenmark Pharmaceuticals Inc
    • Amneal Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd,
    • Novartis AG
    • Zydus Cadila
    • Pfizer Inc,

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global calcium channel blocker drugs Market size is estimated to be valued at US$ 14,285.3 million in 2022 and expected to exhibit a CAGR of 5.2% between 2022 and 2030.
Rising incidence of hypertension and increasing launches and approval of drug is expected to drive the market growth over the forecast period.
Dihydropyridines drug class segment is expected to hold the major market share in the market
North America holds the largest market share in the market.
Major factors hampering the calcium channel blocker drugs market growth include side effect associated with calcium channel blocker drug.
Major players operating in the market include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo